Radiation-Induced Esophageal Cancer: Investigating the Pathogenesis, Management, and Prognosis

被引:5
作者
Syllaios, Athanasios [1 ]
Vailas, Michail [1 ]
Tolia, Maria [2 ]
Charalampakis, Nikolaos [3 ]
Vlachos, Konstantinos [4 ]
Kapetanakis, Emmanouil, I [5 ]
Tomos, Periklis, I [5 ]
Schizas, Dimitrios [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Surg 1, Athens 11527, Greece
[2] Univ Crete, Sch Med, Dept Radiotherapy, Iraklion 71110, Greece
[3] Metaxa Canc Hosp, Dept Med Oncol, Athens 18537, Greece
[4] Univ Hosp Ioannina, Dept Surg, Ioannina 45500, Greece
[5] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Thorac Surg, Athens 12462, Greece
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 07期
关键词
esophageal cancer; radiation; pathogenesis; treatment; prognosis; BREAST-CANCER; CARCINOMA; RADIOTHERAPY; FIELD; RISK; MALIGNANCIES; SURVIVAL; THERAPY; IMPACT;
D O I
10.3390/medicina58070949
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One of the most serious late side effects of irradiation is the promotion of tumorigenesis. Radiation-induced esophageal cancer (RIEC) can arise in a previously irradiated field, mostly in patients previously irradiated for thoracic malignancies such as breast cancer, Hodgkin and non-Hodgkin lymphomas, head and neck cancers, lung cancer, or previous esophageal cancer. RIEC is rare and accounts for less than 1% of all carcinomas of the esophagus. There are little data available in the current literature regarding pathogenesis, diagnosis, treatment, and outcome of esophageal cancer developed in a previously irradiated field. RIEC seems to represent a biologically aggressive disease with a poor prognosis. Although it is difficult to perform radical surgery on a previously irradiated field, R0 resection remains the mainstay of treatment. The use of neoadjuvant and adjuvant chemoradiotherapy remains very helpful in RIEC, similarly to conventional esophageal cancer protocols. The aim of this article is to elucidate this rare but challenging entity.
引用
收藏
页数:8
相关论文
共 31 条
  • [1] Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies
    Adebahr, Sonja
    Schimek-Jasch, Tanja
    Nestle, Ursula
    Brunner, Thomas B.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2016, 30 (04) : 565 - 580
  • [2] Radiation therapy for breast cancer and increased risk for esophageal carcinoma
    Ahsan, H
    Neugut, AI
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (02) : 114 - 117
  • [3] Genetic Features of Metachronous Esophageal Cancer Developed in Hodgkin's Lymphoma or Breast Cancer Long-Term Survivors: An Exploratory Study
    Boldrin, Elisa
    Rumiato, Enrica
    Fassan, Matteo
    Cappellesso, Rocco
    Rugge, Massimo
    Chiarion-Sileni, Vanna
    Ruol, Alberto
    Alfieri, Rita
    Cagol, Matteo
    Castoro, Carlo
    Amadori, Alberto
    Saggioro, Daniela
    [J]. PLOS ONE, 2015, 10 (01):
  • [4] Braakhuis BJM, 2003, CANCER RES, V63, P1727
  • [5] Cahan WG, 1998, CANCER-AM CANCER SOC, V82, P8, DOI 10.1002/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO
  • [6] 2-W
  • [7] Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
    Charalampakis, Nikolaos
    Tsakatikas, Sergios
    Schizas, Dimitrios
    Kykalos, Stylianos
    Tolia, Maria
    Fioretzaki, Rodanthi
    Papageorgiou, Georgios
    Katsaros, Ioannis
    Abdelhakeem, Ahmed Adel Fouad
    Sewastjanow-Silva, Matheus
    Rogers, Jane E.
    Ajani, Jaffer A.
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (01) : 181 - 202
  • [8] Radiation induced secondary malignancies: a review article
    Dracham, Chinna Babu
    Shankar, Abhash
    Madan, Renu
    [J]. RADIATION ONCOLOGY JOURNAL, 2018, 36 (02): : 85 - 94
  • [9] TOLERANCE OF NORMAL TISSUE TO THERAPEUTIC IRRADIATION
    EMAMI, B
    LYMAN, J
    BROWN, A
    COIA, L
    GOITEIN, M
    MUNZENRIDER, JE
    SHANK, B
    SOLIN, LJ
    WESSON, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01): : 109 - 122
  • [10] IS CISPLATIN A HUMAN CARCINOGEN
    GREENE, MH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (05) : 306 - 312